| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months … why not 3 months?
|
Sobrero, A.
|
|
|
16 |
4 |
p. 521-522
|
artikel
|
| 2 |
AJCC Cancer Staging Handbook plus EZTNM
|
Pajk, B.
|
|
|
16 |
4 |
p. 678-679
|
artikel
|
| 3 |
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer
|
Chau, I.
|
|
|
16 |
4 |
p. 549-557
|
artikel
|
| 4 |
Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies
|
Morita, T.
|
|
|
16 |
4 |
p. 640-647
|
artikel
|
| 5 |
Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices
|
Fratino, G.
|
|
|
16 |
4 |
p. 648-654
|
artikel
|
| 6 |
Clinical Oncology—Basic Principles and Practice, 3rd edition
|
Kataja, V.
|
|
|
16 |
4 |
p. 678
|
artikel
|
| 7 |
Consensus meeting for the management of gastrointestinal stromal tumors
Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
|
Blay, J.-Y.
|
|
|
16 |
4 |
p. 566-578
|
artikel
|
| 8 |
Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin
|
Pujol, J.-L.
|
|
|
16 |
4 |
p. 602-610
|
artikel
|
| 9 |
Hematopoietic stem cell transplantation in mantle cell lymphoma
|
Ganti, A.K.
|
|
|
16 |
4 |
p. 618-624
|
artikel
|
| 10 |
HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy
|
Giaccone, G.
|
|
|
16 |
4 |
p. 538-548
|
artikel
|
| 11 |
Interferon-α as maintenance therapy in patients with multiple myeloma
|
Schaar, C.G.
|
|
|
16 |
4 |
p. 634-639
|
artikel
|
| 12 |
Lymphoscintigraphy in pregnant patients with breast cancer: is it really safe?
|
Tek, I.
|
|
|
16 |
4 |
p. 674
|
artikel
|
| 13 |
Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma
|
Raab, M.S.
|
|
|
16 |
4 |
p. 611-617
|
artikel
|
| 14 |
mTOR-targeted therapy of cancer with rapamycin derivatives
|
Vignot, S.
|
|
|
16 |
4 |
p. 525-537
|
artikel
|
| 15 |
Optimised lymphoscintigraphy in pregnant patients with breast cancer is safe
|
Paganelli, G.
|
|
|
16 |
4 |
p. 674-675
|
artikel
|
| 16 |
Perceptions of older people with cancer of information, decision making and treatment: a systematic review of selected literature Ann Oncol 2004; 15: 1596–1602
|
Chouliara, Z.
|
|
|
16 |
4 |
p. 680
|
artikel
|
| 17 |
Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer
|
Camps, C.
|
|
|
16 |
4 |
p. 597-601
|
artikel
|
| 18 |
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse
|
Sureda, A.
|
|
|
16 |
4 |
p. 625-633
|
artikel
|
| 19 |
Reply to the article “Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity” by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543–1550): … and in humans?
|
De Pas, T.
|
|
|
16 |
4 |
p. 673
|
artikel
|
| 20 |
Response to letter “DNA micro- arrays will be instrumental in the future diagnosis of cervical dysplasia and neoplasia”, by P. K. Wright (doi:10.1093/annonc/mdi109)
|
Barranger, E.
|
|
|
16 |
4 |
p. 676
|
artikel
|
| 21 |
Response to “Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics”, by Dannecker et al. (Ann Oncol 2004; 15: 863–869) and “Histopathological validation of the sentinel node concept in cervical cancer”, by Barranger et al. (Ann Oncol 2004; 15: 870–874): DNA microarrays will be instrumental in the future diagnosis of cervical dysplasia and neoplasia
|
Wright, P.K.
|
|
|
16 |
4 |
p. 675-676
|
artikel
|
| 22 |
Response to the letter “DNA microarrays will be instrumental in the future diagnosis of cervical dysplasia and neoplasia”, by P. K. Wright (doi:10.1093/annonc/mdi109): prospective and controlled trials are required to evaluate the relevance of DNA microarrays with regard to diagnosis and therapy of cervical neoplasia
|
Dannecker, C.
|
|
|
16 |
4 |
p. 676-677
|
artikel
|
| 23 |
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
|
Drevs, J.
|
|
|
16 |
4 |
p. 558-565
|
artikel
|
| 24 |
Survival for rectal cancer patients and international comparisons
|
Kerr, J.
|
|
|
16 |
4 |
p. 664-672
|
artikel
|
| 25 |
Table of Contents
|
|
|
|
16 |
4 |
p. ii-iii
|
artikel
|
| 26 |
Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients
|
Moskovitz, B.
|
|
|
16 |
4 |
p. 585-589
|
artikel
|
| 27 |
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer
|
Weinfurt, K.P.
|
|
|
16 |
4 |
p. 579-584
|
artikel
|
| 28 |
Timing of quality of life assessment in cancer clinical trials: fine tuning remains a challenge
|
Bernhard, J.
|
|
|
16 |
4 |
p. 523-524
|
artikel
|
| 29 |
Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma
|
Raspollini, M.R.
|
|
|
16 |
4 |
p. 590-596
|
artikel
|
| 30 |
Use of complementary and alternative medicine in cancer patients: a European survey
|
Molassiotis, A.
|
|
|
16 |
4 |
p. 655-663
|
artikel
|
Tijdschrift beschrijving